What We Are Looking For
Talk to us about how we can work together to bring new medicines to patients.
Kazia welcomes opportunities to discuss potential in-licensing of development candidates for oncology indications.
Our primary focus is on small molecule therapies, with a preference for those that can be orally administered and handled under controlled ambient conditions. We are able to work in all cancer types, but with an emphasis on solid tumour indications.
We are excited by development candidates with first-in-class or best-in-class potential, where there is clear target validation, compelling proof of concept in vivo, a mature GMP manufacturing process, and availability of some GLP toxicology data.
Our focus is on taking development candidates through clinical proof of concept, and so we are less well placed to partner in late-stage programs or commercial products.
Kazia is also pleased to discuss regional or global out-licensing opportunities for development candidates in its current pipeline.
For more information, please contact email@example.com.